PanGen Biotech Inc. (KOSDAQ:222110)

Market Cap	73.91B
Revenue (ttm)	13.72B
Net Income (ttm)	-598.90M
Shares Out	12.90M
EPS (ttm)	-57.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,467
Average Volume	30,509
Open	5,480.00
Previous Close	5,480.00
Day's Range	5,400.00 - 5,810.00
52-Week Range	3,750.00 - 7,770.00
Beta	0.01
RSI	59.52
Earnings Date	n/a

About PanGen Biotech

PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service. PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 222110

Financial Performance

In 2023, PanGen Biotech's revenue was 7.32 billion, an increase of 12.53% compared to the previous year's 6.50 billion. Losses were -4.49 billion, -0.11% less than in 2022.